Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, deals, RNA Interference

MDRNA Gains Full Rights to Drug Technology

Luke Timmerman 6/19/09

MDRNA, the Bothell, WA-based developer of RNA interference drug technology, said today it has renegotiated a key technology license so that it has full control and no longer needs to make future payments for it. MDRNA (NASDAQ: MRNA) bought the rights in October to unlocked nucleobase analog technology from Denmark-based RiboTask, which has been studying its ability to make RNA interference drugs more stable, and less likely to spark inflammation. Terms of the deal with RiboTask weren’t disclosed, although MDRNA raised $10.5 million from investors this month.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.


Links to This Post

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.